ASA 81 mg vs 162 mg During Frozen Embryo Transfer (FET)

NCT ID: NCT06128395

Last Updated: 2025-12-09

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 1207 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2023-11-01
• Study Completion Date: 2024-09-18

Brief Summary

The use of low dose aspirin is recommended for high risk patients to reduce the risk of pre-eclampsia, placental abruption and antepartum hemorrhage. Recent studies have shown that in a specific population, the use of low dose aspirin might reduce the risk of preterm birth in pregnant women with singleton pregnancy. In June 2022, clinique ovo started implementing the use of Aspirin 162 mg instead of 81 mg in the frozen embryo transfer cycles based on recent study outcomes. The use of Aspirin 162 mg might have additional benefits on the embryo transfer outcomes by decreasing the miscarriage. Moreover this can be continued until late in pregnancy without adverse effects.

Conditions

Fertility Disorders

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: RETROSPECTIVE

Study Groups

Aspirin 81 mg for Frozen Embryo Transfer (FET)

Subjects were prescribed Aspirin 81 mg to be started on the third day of their menstrual cycle in preparation for their FET.

Frozen embryo transfer

Intervention Type: OTHER

A frozen embryo transfer involves thawing a fertilized embryo and transferring it in the uterus in order to obtain a pregnancy

Aspirin 162 mg for Frozen Embryo Transfer (FET)

Subjects were prescribed Aspirin 162 mg to be started on the third day of their menstrual cycle in preparation for their FET

Frozen embryo transfer

Intervention Type: OTHER

A frozen embryo transfer involves thawing a fertilized embryo and transferring it in the uterus in order to obtain a pregnancy

Interventions

Frozen embryo transfer

A frozen embryo transfer involves thawing a fertilized embryo and transferring it in the uterus in order to obtain a pregnancy

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Women taking aspirin 81 mg or 162 mg prior to an autologous embryo transfer
• Age < 40 years old
• Embryo transfer cycle done at clinique ovo

Exclusion Criteria

• Egg or embryo recipient
• History of recurrent miscarriages, defined as ≥ 3 consecutive losses
• Patients that needed Viagra, PRP or other modalities to improve their endometrial thickness
• Uterine factor infertility
• Abnormal hormonal profiles
• Stimulated embryo transfer cycles
• History of recurrent implantation failure defined as failed ≥ 2 euploid embryos transfer or ≥ 3 blastocysts

• Maximum Eligible Age: 40 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Clinique Ovo

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Wael Jamal, MD

Role: PRINCIPAL_INVESTIGATOR

Clinique Ovo

Locations

Clinique Ovo

Montreal, Quebec, Canada

Countries

Canada

Other Identifiers

3384

Identifier Type: -

Identifier Source: org_study_id